z-logo
open-access-imgOpen Access
Cabozantinib enhances the response of NSCLC cells with wild-type EGFR to erlotinib and pharmacodynamic modeling of their sequential combinations
Author(s) -
Zhen-zhen Mou
Publication year - 2016
Publication title -
journal of chinese pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.138
H-Index - 12
ISSN - 1003-1057
DOI - 10.5246/jcps.2016.11.089
Subject(s) - erlotinib , cabozantinib , pharmacodynamics , pharmacology , medicine , oncology , cancer research , pharmacokinetics , epidermal growth factor receptor , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom